Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099021 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00099021: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00099021 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099021, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be effective in preventing head and neck cancer.
Interventions
- DRUG pioglitazone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099021
The ClinicalTrials.gov registry entry for NCT00099021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pioglitazone hydrochloride is the first listed.
NCT00099021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099021 about?
NCT00099021 is a clinical study titled "Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia". This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be ...
What is the current status of trial NCT00099021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2003-06. Estimated completion is 2008-06-27.
What interventions are being tested in trial NCT00099021?
The interventions under investigation include: pioglitazone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00099021?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.